
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Details : CPO301 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 17, 2023

Details : CPO102 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 14, 2021

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Details : CPO-100 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 18, 2021

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CPO107
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CPO107 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, Non-Hodgkin.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 21, 2021
Lead Product(s) : CPO107
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Butylphthalide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : CSPC-NBP Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
Details : N-Butylphthalide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 19, 2020
Lead Product(s) : Butylphthalide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : CSPC-NBP Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Levoamlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Levamlodipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 05, 2018
Lead Product(s) : Levoamlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HA115
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers
Details : HA115 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 26, 2018
Lead Product(s) : HA115
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PLM60
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : CSPC ZhongQi
Deal Size : Inapplicable
Deal Type : Inapplicable
PLM60 for Peripheral T Cell Lymphoma (PTCL)
Details : PLM60 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 12, 2018
Lead Product(s) : PLM60
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : CSPC ZhongQi
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All